Pancreatic Cancer Research

ResearcherFirst Hospital of China Medical UniversityActive in the last 2 years

Qingfeng Liu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5360-169X; OpenAlex author ID A5100349225. Sources: OpenAlex.

Their work

Papers
9 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
10
Papers, trials and grants by year

2013: 2 papers · 2014: 2 papers · 2015: 1 paper · 2016: none · 2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: none · 2022: 2 papers · 2023: none · 2024: none · 2025: 1 paper

Papers 9

  1. Prognostic analysis and mechanistic exploration of the autophagy-related exosome genes ITGA3, ITGB4, and PTK6 in pancreatic ductal adenocarcinoma. Last author DOI 10.1007/s12672-025-03061-6↗
  2. Correction: Musashi2 promotes the development and progression of pancreatic cancer by down-regulating Numb protein. Co-author DOI 10.18632/oncotarget.28157↗
  3. Syntenin Regulated by miR-216b Promotes Cancer Progression in Pancreatic Cancer. Co-author DOI 10.3389/fonc.2022.790788↗
  4. Musashi2 promotes the development and progression of pancreatic cancer by down-regulating Numb protein. Co-author DOI 10.18632/oncotarget.8736↗
  5. Gli1 promotes transforming growth factor-beta1- and epidermal growth factor-induced epithelial to mesenchymal transition in pancreatic cancer cells. Co-author DOI 10.1016/j.surg.2015.03.016↗
  6. The clinicopathological significance and relationship of Gli1, MDM2 and p53 expression in resectable pancreatic cancer. Co-author DOI 10.1111/his.12273↗
  7. [The role of Gli1 in the invasion and migration of pancreatic cancer cells]. Co-author PMID 25262609↗
  8. Cooperation among Numb, MDM2 and p53 in the development and progression of pancreatic cancer. Co-author DOI 10.1007/s00441-013-1679-6↗
  9. [Correlation between Gli1 expression and clinicopathological significance in human pancreatic cancer]. Co-author PMID 24433772↗

Closest collaborators

The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Qi Dong · 7 shared papers, 2013–2022 · strength 0.51
  2. Weiwei Sheng · 7 shared papers, 2013–2022 · strength 0.51
  3. Fuqiang Zu · 2 shared papers, 2022–2025 · strength 0.47
  4. Ming Dong · 5 shared papers, 2013–2022 · strength 0.42
  5. Lunbing Liang · 1 shared paper, 2025 · strength 0.28
  6. Hui Chen · 1 shared paper, 2022 · strength 0.19
  7. Xiaodong Tan · 1 shared paper, 2022 · strength 0.19
  8. Jianping Zhou · 4 shared papers, 2013–2014 · strength 0.18
  9. Feng Li · 3 shared papers, 2013–2015 · strength 0.15
  10. Xin Li · 1 shared paper, 2013 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.